ESOPs for Contractors: Sell to Your Team, Keep the Mission
Your team built this business with you. An ESOP lets them own it — and gives you a tax-advantaged exit.
The PE firm offers $4M for your HVAC company. Clean deal, good multiple. But your lead tech has been with you since year two. Your office manager runs the place while you're on vacation. Your installers are the reason clients stay. Selling to PE means their jobs are "optimized" within 18 months.
An ESOP offers an alternative: sell to your team, defer your capital gains, and preserve the culture you built.
How It Works
The company establishes an ESOP trust. The trust borrows money (often from a bank, sometimes from the seller) to buy your shares. The company makes annual tax-deductible contributions to repay the loan. Employees receive allocated shares through vesting — they literally become owners.
For C-corps, §1042 rollover lets you defer capital gains indefinitely by reinvesting sale proceeds into Qualified Replacement Property (stocks, bonds of domestic operating companies) within 12 months. For S-corps, the ESOP-owned portion of the company's income is exempt from federal income tax.
The Real Numbers
$4M sale to PE: you net roughly $2.8M after federal and state taxes. $4M sale to ESOP (C-corp, §1042): you receive $4M, defer the gain, invest in a diversified portfolio. The tax savings compound for decades.
Who This Fits
Contractors with: stable revenue ($3M+), loyal long-term employees, a desire to preserve company culture, and willingness to invest 6-12 months in setup. ESOP feasibility studies cost $20K-$40K; full implementation runs $100K-$150K. The tax benefits typically dwarf the costs.
This pairs with exit planning, installment sales, and the tax strategy guide.
Want to Know If This Strategy Fits Your Business?
I'll review your situation, run the numbers, and tell you straight whether this move makes sense. Free 20-minute call — no pitch, just math.
Keep Reading
25 years helping contractors close the gap between bid and bank. Over 100,000 returns reviewed.